ArticleCureus2024
Essential Thrombocythemia Possible Cause of Ischemic Cerebrovascular Disease: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Essential thrombocythemia (ET) is a rare, chronic myeloproliferative neoplasm characterized by the overproduction of platelets. ET is of significant clinical importance due to thrombotic and hemorrhagic cerebrovascular disease. The JAK2 V617F mutation has been identified in approximately 50-60% of ET cases. Our case report: a 41-year-old male presented to the hospital with a one-day history of vertigo, ataxic gait, and vomiting. The patient was diagnosed with ET at an external center two years ago. The JAK2 V617F mutation was detected. He regularly uses acetylsalicylic acid 100 mg per day. Magnetic resonance imaging (MRI) showed an acute infarction involving the bilateral cerebellar hemisphere, thalamic area, and right occipital area. Computed Tomography Angiography showed that no significant stenosis was detected in major branches. The patient was diagnosed with ischemic cerebrovascular disease for ET. Antiplatelet therapy was started with acetylsalicylic acid 100 mg and clopidogrel 75 mg once a day. With the recommendation of hematology, cytoreductive treatment, hydroxyurea 1000 mg twice a day, was started. The patient's complaints were resolved at the end of the second day, and the patient with minimal ataxia was discharged with recommendations. Patients with ET should be aware of ischemic cerebrovascular disease and consider antiplatelet and cytoreductive treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.